{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:51:23Z","timestamp":1790599883512,"version":"4.1.0"},"reference-count":38,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Parkinson\u2019s Disease"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Data-driven approaches identified Mild Motor Predominant (MMP), Intermediate (IM), and Diffuse Malignant (DM) as Parkinson's Disease (PD) subtypes with different motor and non-motor impairment at diagnosis. It remains unclear whether these subtypes remain stable over time or whether they represent distinct biological substrates. The alpha-synuclein seed amplification assay in CSF (CSF-\u03b1Syn-SAA) might provide further insights.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>to evaluate the association between baseline CSF-\u03b1Syn-SAA parameters and 10-year clinical evolution of PD subtypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>323 sporadic PD patients from PPMI dataset were classified as MMP, IM, or DM at baseline and 10-year follow-up based on motor, cognitive, sleep and dysautonomia features. CSF-\u03b1Syn-SAA parameters were collected at baseline using 150-h protocol. CSF A\u03b21-42, tTau and pTau181, CSF and serum NfL were also considered at baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Reaction times (T50, TTT) and area under the curve (AUC) respectively were shorter and larger in DM compared to IM\/MMP. The difference in baseline amplification parameters was more evident when comparing subtypes based on 10-year clinical features (T50, \u03b72\u2009=\u20090.036; TTT, \u03b72\u2009=\u20090.031; AUC, \u03b72\u2009=\u20090.033; all p-values &lt; 0.05) than when comparing subtypes based on baseline clinical features (T50, \u03b72\u2009=\u20090.012; TTT, \u03b72\u2009=\u20090.012; AUC, \u03b72\u2009=\u20090.013; all p\u2009&lt;\u20090.05). Shorter T50 and TTT at baseline, or larger AUC, were associated with greater risk of DM versus MMP at 10-year follow-up (T50, OR = 4.1, p\u2009=\u20090.004; TTT, OR = 5.5, p\u2009&lt;\u20090.001; AUC, OR = 3.5, p\u2009=\u20090.010). A\u03b2, Tau and NfL were similar between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Baseline CSF-\u03b1Syn-SAA parameters predicted long-term PD progression. Faster reactions were associated with a more severe 10-year PD phenotype considering motor and non-motor features.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1877718x261417468","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T19:15:04Z","timestamp":1769714104000},"page":"233-245","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Faster reaction times of CSF alpha-synuclein seed amplification assay predict the diffuse malignant subtype of Parkinson's disease at 10-year follow-up"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-3914","authenticated-orcid":false,"given":"Piergiorgio","family":"Grillo","sequence":"first","affiliation":[{"name":"Department of Neurology, The Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders, NYU Langone Health, NY, USA"},{"name":"Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy"},{"name":"IRCCS Mondino Foundation, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0322-5718","authenticated-orcid":false,"given":"Giulietta Maria","family":"Riboldi","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders, NYU Langone Health, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8432-594X","authenticated-orcid":false,"given":"Antonio","family":"Pisani","sequence":"additional","affiliation":[{"name":"Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy"},{"name":"IRCCS Mondino Foundation, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5970-6839","authenticated-orcid":false,"given":"Un Jung","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders, NYU Langone Health, NY, USA"},{"name":"Department of Neuroscience, Institute for Translational Neuroscience, and Parekh Center for Interdisciplinary Neurology, NYU Grossman School of Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9255-9351","authenticated-orcid":false,"given":"Seyed-Mohammad","family":"Fereshtehnejad","sequence":"additional","affiliation":[{"name":"The Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, Toronto, ON, Canada"},{"name":"Division of Neurology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada"},{"name":"Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00218-X"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-202472"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25383"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2019.06.017"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00486-9"},{"key":"e_1_3_3_7_2","article-title":"Dysautonomia and REM sleep behavior disorder contributions to progression of Parkinson\u2019s disease phenotypes","volume":"8","author":"Riboldi GM","unstructured":"Riboldi GM, Russo MJ, Pan L, et al. Dysautonomia and REM sleep behavior disorder contributions to progression of Parkinson\u2019s disease phenotypes. NPJ Parkinsons Dis 2022 Dec 1; 8.","journal-title":"NPJ Parkinsons Dis"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx118"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2015.0703"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.1040405"},{"key":"e_1_3_3_11_2","first-page":"1","article-title":"Two-year clinical progression in focal and diffuse subtypes of Parkinson\u2019s disease","volume":"9","author":"Johansson ME","unstructured":"Johansson ME, van Lier NM, Kessels RPC, et al. Two-year clinical progression in focal and diffuse subtypes of Parkinson\u2019s disease. npj Parkinson\u2019s Disease 2023 Feb 17; 9: 1\u201311.","journal-title":"npj Parkinson\u2019s Disease"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.13710"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-022-00787-3"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00109-6"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-1984-7"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.30085"},{"key":"e_1_3_3_17_2","first-page":"1","article-title":"CSF \u03b1-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson\u2019s disease","volume":"10","author":"Brockmann K","unstructured":"Brockmann K, Lerche S, Baiardi S, et al. CSF \u03b1-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson\u2019s disease. NPJ Parkinson\u2019s Disease 2024 Jan 20; 10: 1\u20139.","journal-title":"NPJ Parkinson\u2019s Disease"},{"key":"e_1_3_3_18_2","first-page":"16","article-title":"Alpha-synuclein seed amplification assay longitudinal outcomes in Lewy body disease spectrum","volume":"139","author":"Mastrangelo A","unstructured":"Mastrangelo A, Mammana A, Hall S, et al. Alpha-synuclein seed amplification assay longitudinal outcomes in Lewy body disease spectrum. Brain 2024 Dec 17; 139: 16\u201317.","journal-title":"Brain"},{"key":"e_1_3_3_19_2","first-page":"1","article-title":"Kinetic parameters of alpha-synuclein seed amplification assay correlate with cognitive impairment in patients with Lewy body disorders","volume":"11","author":"Br\u00e4uer S","unstructured":"Br\u00e4uer S, Rossi M, Sajapin J, et al. Kinetic parameters of alpha-synuclein seed amplification assay correlate with cognitive impairment in patients with Lewy body disorders. Acta Neuropathol Commun 2023 Dec 1; 11: 1\u20139.","journal-title":"Acta Neuropathol Commun"},{"key":"e_1_3_3_20_2","article-title":"\u03b1-Synuclein seed amplification assay amplification parameters and the risk of progression in prodromal Parkinson disease","volume":"104","author":"Coughlin DG","unstructured":"Coughlin DG, Shifflett B, Farris CM, et al. \u03b1-Synuclein seed amplification assay amplification parameters and the risk of progression in prodromal Parkinson disease. Neurology 2025 Mar 11; 104: e210279.","journal-title":"Neurology"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29708"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2021.05.016"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2017.07.018"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2016.04.027"},{"key":"e_1_3_3_25_2","first-page":"1","article-title":"High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson\u2019s disease","volume":"9","author":"Russo MJ","unstructured":"Russo MJ, Orru CD, Concha-Marambio L, et al. High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson\u2019s disease. Acta Neuropathol Commun 2021 Dec 1; 9: 1\u201313.","journal-title":"Acta Neuropathol Commun"},{"key":"e_1_3_3_26_2","article-title":"A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson\u2019s disease","volume":"149","author":"Bernhardt AM","unstructured":"Bernhardt AM, Longen S, Trossbach SV, et al. A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson\u2019s disease. Acta Neuropathol 2025 Jun 1; 149.","journal-title":"Acta Neuropathol"},{"key":"e_1_3_3_27_2","article-title":"Quantification of Lewy body pathology by cerebrospinal fluid endpoint dilution RT-QuIC in a neuropathological autopsy cohort of clinically heterogeneous participants","volume":"149","author":"Mastrangelo A","unstructured":"Mastrangelo A, Caldera S, Mastenbroek SE, et al. Quantification of Lewy body pathology by cerebrospinal fluid endpoint dilution RT-QuIC in a neuropathological autopsy cohort of clinically heterogeneous participants. Acta Neuropathol 2025 Jun 1; 149.","journal-title":"Acta Neuropathol"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/1877718X251379292"},{"key":"e_1_3_3_29_2","first-page":"1","article-title":"Performance of a seed amplification assay for misfolded alpha-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden","volume":"147","author":"Bentivenga GM","unstructured":"Bentivenga GM, Mammana A, Baiardi S, et al. Performance of a seed amplification assay for misfolded alpha-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden. Acta Neuropathol 2024 Jun 1; 147: 1\u201313.","journal-title":"Acta Neuropathol"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00157-7"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2024.2403073"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.4377"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29005"},{"key":"e_1_3_3_34_2","first-page":"1","article-title":"Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson\u2019s disease","volume":"15","author":"Ng ASL","unstructured":"Ng ASL, Tan YJ, Yong ACW, et al. Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson\u2019s disease. Mol Neurodegener 2020 Jun 5; 15: 1\u20138.","journal-title":"Mol Neurodegener"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-023-02632-7"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-022-02464-x"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-023-02251-9"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-011-0708-4"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2021.04.016"}],"container-title":["Journal of Parkinson\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X261417468","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1877718X261417468","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X261417468","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:51:42Z","timestamp":1790254302000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1877718X261417468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1177\/1877718X261417468"],"URL":"https:\/\/doi.org\/10.1177\/1877718x261417468","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]}}}